newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

  • IGC Pharma announced in-vitro findings that IGC-1C targets the liquid-liquid phase separation (LLPS) of tau protein, a critical early pathway in Alzheimer's disease.
  • IGC-1C demonstrated the ability to inhibit the formation of zinc-mediated tau condensates while promoting their dissolution to prevent neurotoxic tangle formation.
  • The compound exhibited a high binding affinity for tau with a dissociation constant (Kd) of 3.95 ± 0.32 μM.
  • Microscopy assays confirmed that IGC-1C reduces both the size & number of tau-zinc condensates & their conversion into toxic amyloid fibrils.
  • Cellular compatibility was established in SH-SY5Y neuroblastoma cultures, showing the compound is well-tolerated & permeable.
  • IGC-1C's structure utilizes three chemical motifs: zinc chelation via a dipicolylamine group, interaction disruption through naphthalimide & aromatic rings, & multivalency stabilization via a cyclic dipeptide core.
  • The mechanism is distinct from existing therapies & offers potential expansion into other conditions involving LLPS, such as cancer & ALS.
  • IGC Pharma plans to conduct further validation studies in animal models with the long-term goal of advancing IGC-1C toward clinical trials.